Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
NCT01780220
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
Interventions
DRUG:
Abiraterone
Sponsor
UNICANCER